Literature DB >> 8122957

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.

J H Krystal1, L P Karper, J P Seibyl, G K Freeman, R Delaney, J D Bremner, G R Heninger, M B Bowers, D S Charney.   

Abstract

BACKGROUND: To characterize further behavioral, cognitive, neuroendocrine, and physiological effects of subanesthetic doses of ketamine hydrochloride in healthy human subjects. Ketamine, a phencyclidine hydrochloride derivative, is a dissociative anesthetic and a noncompetitive antagonist of the N-methyl-D-aspartate subtype of excitatory amino acid receptor.
METHODS: Nineteen healthy subjects recruited by advertisements from the community participated in this randomized, double-blind, placebo-controlled study. Subjects completed three test days involving the 40-minute intravenous administration of placebo, ketamine hydrochloride (0.1 mg/kg), or ketamine hydrochloride (0.5 mg/kg). Behaviors associated with the positive and negative symptoms of schizophrenia were assessed by using the Brief Psychiatric Rating Scale. Changes in perception and behaviors associated with dissociative states were assessed by the Perceptual Aberration Subscale of the Wisconsin Psychosis Proneness Scale and the Clinician-Administered Dissociative States Scale. Cognitive function was assessed by using the (1) Mini-Mental State Examination; (2) tests sensitive to frontal cortical dysfunction, including a continuous performance vigilance task, a verbal fluency task, and the Wisconsin Card Sorting Test; and (3) tests of immediate and delayed recall. Plasma levels of cortisol, prolactin, homovanillic acid, and 3-methoxy-4-hydroxyphenethyleneglycol were measured.
RESULTS: Ketamine (1) produced behaviors similar to the positive and negative symptoms of schizophrenia; (2) elicited alterations in perception; (3) impaired performance on tests of vigilance, verbal fluency, and the Wisconsin Card Sorting Test; (4) evoked symptoms similar to dissociative states; and (5) preferentially disrupted delayed word recall, sparing immediate recall and postdistraction recall. Ketamine had no significant effect on the Mini-Mental State Examination at the doses studied. Ketamine also had no effect on plasma 3-methoxy-4-hydroxyphenethyleneglycol levels, although it blunted a test day decline in plasma homovanillic acid levels at the higher dose. It also dose dependently increased plasma cortisol and prolactin levels. Ketamine produced small dose-dependent increases in blood pressure.
CONCLUSIONS: These data indicate that N-methyl-D-aspartate antagonists produce a broad range of symptoms, behaviors, and cognitive deficits that resemble aspects of endogenous psychoses, particularly schizophrenia and dissociative states.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8122957     DOI: 10.1001/archpsyc.1994.03950030035004

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  977 in total

1.  Synaptic basis of cortical persistent activity: the importance of NMDA receptors to working memory.

Authors:  X J Wang
Journal:  J Neurosci       Date:  1999-11-01       Impact factor: 6.167

Review 2.  Animal models of schizophrenia: a critical review.

Authors:  E R Marcotte; D M Pearson; L K Srivastava
Journal:  J Psychiatry Neurosci       Date:  2001-11       Impact factor: 6.186

Review 3.  Contribution of Vesicular Glutamate Transporters to Stress Response and Related Psychopathologies: Studies in VGluT3 Knockout Mice.

Authors:  Hanga Réka Horváth; Csilla Lea Fazekas; Diána Balázsfi; Subodh Kumar Jain; József Haller; Dóra Zelena
Journal:  Cell Mol Neurobiol       Date:  2017-08-03       Impact factor: 5.046

4.  Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.

Authors:  Surendra P Singh; Vidhi Singh
Journal:  CNS Drugs       Date:  2011-10-01       Impact factor: 5.749

5.  The Behavioral and Pharmacological Actions of NMDA Receptor Antagonism are Conserved in Zebrafish Larvae.

Authors:  John Chen; Roshni Patel; Theodore C Friedman; Kevin S Jones
Journal:  Int J Comp Psychol       Date:  2010

Review 6.  Defects in Bioenergetic Coupling in Schizophrenia.

Authors:  Courtney R Sullivan; Sinead M O'Donovan; Robert E McCullumsmith; Amy Ramsey
Journal:  Biol Psychiatry       Date:  2017-10-24       Impact factor: 13.382

Review 7.  Aberrant Network Activity in Schizophrenia.

Authors:  Mark J Hunt; Nancy J Kopell; Roger D Traub; Miles A Whittington
Journal:  Trends Neurosci       Date:  2017-05-14       Impact factor: 13.837

8.  Ketamine impairs multiple cognitive domains in rhesus monkeys.

Authors:  Michael A Taffe; Sophia A Davis; Tannia Gutierrez; Lisa H Gold
Journal:  Drug Alcohol Depend       Date:  2002-10-01       Impact factor: 4.492

9.  Ketamine Suppresses the Ventral Striatal Response to Reward Anticipation: A Cross-Species Translational Neuroimaging Study.

Authors:  Jennifer Francois; Oliver Grimm; Adam J Schwarz; Janina Schweiger; Leila Haller; Celine Risterucci; Andreas Böhringer; Zhenxiang Zang; Heike Tost; Gary Gilmour; Andreas Meyer-Lindenberg
Journal:  Neuropsychopharmacology       Date:  2015-09-21       Impact factor: 7.853

10.  Neural activation deficits in a mouse genetic model of NMDA receptor hypofunction in tests of social aggression and swim stress.

Authors:  Gary E Duncan; Ken Inada; Joseph S Farrington; Beverly H Koller; Sheryl S Moy
Journal:  Brain Res       Date:  2009-02-13       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.